We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+17.11%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$174M
AUM Growth
+$23.9M
Cap. Flow
+$13.2M
Cap. Flow %
7.62%
Top 10 Hldgs %
75.05%
Holding
53
New
3
Increased
5
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
BDSX icon
Biodesix
BDSX
+$17.2M
2
FHTX icon
Foghorn Therapeutics
FHTX
+$6.02M
3
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$1.47M
4
ALBO
Albireo Pharma Inc
ALBO
+$1.24M
5
KPTI icon
Karyopharm Therapeutics
KPTI
+$309K

Top Sells

Rank Stock Value
1
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$10M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$1.36M
3
EPZM
Epizyme, Inc
EPZM
+$835K
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$344K
5
VYGR icon
Voyager Therapeutics
VYGR
+$320K

Sector Composition

Rank Sector Weight
1 Healthcare 96.79%
2 Energy 1.15%
3 Consumer Staples 0.06%
4 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
DELISTED
Immunogen Inc
IMGN
$1.23M 0.71%
190,000
– –
ETRN
27
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$1.07M 0.62%
133,050
– –
VNDA icon
28
Vanda Pharmaceuticals
VNDA
$312M
$1.05M 0.61%
80,000
– –
CFRX
29
DELISTED
ContraFect Corporation
CFRX
$1.01M 0.58%
2,500
-696
-22% -$301K
FOLD
30
DELISTED
Amicus Therapeutics
FOLD
$877K 0.51%
38,000
– –
BHVN
31
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$857K 0.49%
10,000
– –
TGTX icon
32
TG Therapeutics
TGTX
$8.58B
$780K 0.45%
15,000
– –
BMY.RT
33
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
$763K 0.44%
1,105,313
-101,535
-8% -$216K
GTHX
34
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$720K 0.41%
40,000
– –
PGNY icon
35
Progyny
PGNY
$2.44B
$636K 0.37%
15,000
– –
CLR
36
DELISTED
CONTINENTAL RESOURCES INC.
CLR
$629K 0.36%
38,600
– –
NARI
37
DELISTED
Inari Medical, Inc. Common Stock
NARI
$611K 0.35%
7,000
– –
KALV
38
DELISTED
KalVista Pharmaceuticals
KALV
$570K 0.33%
30,000
– –
TBIO
39
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$553K 0.32%
30,000
– –
XNCR icon
40
Xencor
XNCR
$1.44B
$537K 0.31%
12,300
– –
OVV icon
41
Ovintiv
OVV
$17.5B
$493K 0.28%
34,350
– –
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
$458K 0.26%
8,000
– –
PXD
43
DELISTED
Pioneer Natural Resource Co.
PXD
$433K 0.25%
3,800
– –
ODT
44
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$384K 0.22%
20,000
– –
IFRX icon
45
InflaRx
IFRX
$256M
$352K 0.2%
70,000
– –
DRNA
46
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$220K 0.13%
10,000
– –
BCRX icon
47
BioCryst Pharmaceuticals
BCRX
$2.37B
$149K 0.09%
20,000
– –
YTEN
48
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$110K 0.06%
790
– –
VYGR icon
49
Voyager Therapeutics
VYGR
$187M
– –
-30,000
Closed -$320K
WKHS icon
50
Workhorse Group
WKHS
$29.5M
– –
-3
Closed -$202K
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q4 2020 Portfolio in Review

As of Q4 2020, Birchview Capital held 53 positions worth $174M, up 16% from $150M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Birchview Capital deployed $13.2M of net new capital in Q4 2020, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Biodesix: 55,254 shares worth $22.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Energy and Consumer Staples.

On the sell side, the largest reduction was Aspira Women's Health Inc. Common Stock, an estimated $10M trimmed.

  • Birchview Capital's largest Q4 2020 buy was Biodesix: 55,254 shares worth $22.3M.
  • Birchview Capital added most to Albireo Pharma Inc in Q4 2020, an estimated $1.24M increase.
  • Birchview Capital's biggest Q4 2020 reduction was Aspira Women's Health Inc. Common Stock, cutting an estimated $10M.
  • Birchview Capital fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $1.36M.
  • Birchview Capital's ten largest holdings make up 75% of its $174M portfolio in Q4 2020.
  • Birchview Capital opened 3 new positions and closed 5 in Q4 2020.
  • Birchview Capital's portfolio value rose 16% quarter-over-quarter to $174M.

Based on Birchview Capital's 13F filing for Q4 2020, filed 9 Feb 2021.